Approval · Notice of Compliance 28353 · 2022
NEXGARD: Notice of Compliance 28353
Issued June 9, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 28353
- Date
- June 9, 2022
- Company
- Boehringer Ingelheim Animal Health Canada Inc.Burlington, Ontario, Canada
- Product type
- Veterinary
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New indication
Products in this notice
Medicinal ingredients
- AFOXOLANER 11.3 MG per TAB
- AFOXOLANER 28.3 MG per TAB
- AFOXOLANER 68 MG per TAB
- AFOXOLANER 136 MG per TAB